Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Receivables - Other (2016 - 2025)

Historic Receivables - Other for China Pharma Holdings (CPHI) over the last 16 years, with Q3 2025 value amounting to $61275.0.

  • China Pharma Holdings' Receivables - Other rose 3162.42% to $61275.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $61275.0, marking a year-over-year increase of 3162.42%. This contributed to the annual value of $30286.0 for FY2024, which is 8082.48% down from last year.
  • China Pharma Holdings' Receivables - Other amounted to $61275.0 in Q3 2025, which was up 3162.42% from $48361.0 recorded in Q2 2025.
  • China Pharma Holdings' Receivables - Other's 5-year high stood at $1.7 million during Q3 2021, with a 5-year trough of $28660.0 in Q2 2024.
  • In the last 5 years, China Pharma Holdings' Receivables - Other had a median value of $61275.0 in 2025 and averaged $551357.2.
  • As far as peak fluctuations go, China Pharma Holdings' Receivables - Other plummeted by 9795.53% in 2022, and later soared by 44203.64% in 2023.
  • China Pharma Holdings' Receivables - Other (Quarter) stood at $1.4 million in 2021, then crashed by 97.96% to $29139.0 in 2022, then surged by 442.04% to $157944.0 in 2023, then plummeted by 80.82% to $30286.0 in 2024, then surged by 102.32% to $61275.0 in 2025.
  • Its last three reported values are $61275.0 in Q3 2025, $48361.0 for Q2 2025, and $39046.0 during Q1 2025.